Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Dec 14, 2016
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 fourth quarter and year ended September 30, 2016. The company is hosting a conference call at 4:30 p.m...
Dec 7, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, December 14, 2016, at 4:30 p.m. EST to discuss its financial results for the fiscal 2016 year ended September 30, 2016. Conferen...
Nov 29, 2016
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company's new proprietary subcutaneou...
Nov 21, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is pleased to announce that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination of the waiting period under the Hart-Scott Rodino Antit...
Nov 14, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoprotein (a), for the treatment of cardiovascular disease, and ARC-F12, its preclinical development program targeting factor XII (F12) ...
Nov 14, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) delivered a poster presentation with Phase 1 clinical data and an oral presentation with preclinical data on ARC-AAT, its investigational medicine for the treatment of liver disease associated with alpha-1 antitrypsin defi...
Nov 8, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidate under clinical investigation for the treatment of chronic hepatitis B virus (HBV) infection. Heparc-2004 is a multicenter, randomized, ...
Nov 1, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25th Annual Credit Suisse Healthcare Conference - Scottsdale, AZ, November 6-8, 2016 November 7, 11:30 a.m. MST - Christopher An...
Oct 20, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company's investigational medicine for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), at The Liver Meeting® 2016, ...
Oct 6, 2016
PASADENA, Calif. & HOPKINTON, Mass.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase